Trial Profile

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC 704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 22 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Carboplatin; Carboplatin; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer
Focus Registrational; Therapeutic Use

30 Apr 2026 Planned End Date changed from 12 Mar 2026 to 12 Mar 2027.
20 Mar 2025 Planned End Date changed from 1 Mar 2025 to 12 Mar 2026.
27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com